JP2004527508A - 鎮痛剤としての置換されたピラゾロ−及びチアゾロピリミジン類 - Google Patents

鎮痛剤としての置換されたピラゾロ−及びチアゾロピリミジン類 Download PDF

Info

Publication number
JP2004527508A
JP2004527508A JP2002571501A JP2002571501A JP2004527508A JP 2004527508 A JP2004527508 A JP 2004527508A JP 2002571501 A JP2002571501 A JP 2002571501A JP 2002571501 A JP2002571501 A JP 2002571501A JP 2004527508 A JP2004527508 A JP 2004527508A
Authority
JP
Japan
Prior art keywords
phenyl
alkyl
aryl
tetrahydro
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002571501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004527508A5 (enExample
Inventor
ゲルラッハ・マティアス
マウル・コリンナ
ヤグシュ・ウツ−ペーター
ズンダーマン・ベルント
フーア・マルチン
イェッツェルマン・アドリアーン・ペー
ディッセン−デ−グローテ・ミリアム
Original Assignee
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001112197 external-priority patent/DE10112197A1/de
Priority claimed from DE2001153344 external-priority patent/DE10153344A1/de
Application filed by グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング filed Critical グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Publication of JP2004527508A publication Critical patent/JP2004527508A/ja
Publication of JP2004527508A5 publication Critical patent/JP2004527508A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2002571501A 2001-03-14 2002-03-13 鎮痛剤としての置換されたピラゾロ−及びチアゾロピリミジン類 Pending JP2004527508A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2001112197 DE10112197A1 (de) 2001-03-14 2001-03-14 Substituierte Pyrazolo- und Thiazolopyrimidine
DE2001153344 DE10153344A1 (de) 2001-10-29 2001-10-29 Verwendung von substituierten Pyrazolopyrimidinen als Liganden von Nucleosid-Transport-Proteinen und/oder von Purinorezeptoren
PCT/EP2002/002722 WO2002072585A2 (de) 2001-03-14 2002-03-13 Substituierte pyrazolo- und thiazolopyrimidine als analgetika

Publications (2)

Publication Number Publication Date
JP2004527508A true JP2004527508A (ja) 2004-09-09
JP2004527508A5 JP2004527508A5 (enExample) 2010-06-03

Family

ID=26008763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002571501A Pending JP2004527508A (ja) 2001-03-14 2002-03-13 鎮痛剤としての置換されたピラゾロ−及びチアゾロピリミジン類

Country Status (24)

Country Link
US (1) US7135568B2 (enExample)
EP (2) EP1368355B1 (enExample)
JP (1) JP2004527508A (enExample)
KR (1) KR20030082982A (enExample)
CN (1) CN1318422C (enExample)
AT (2) ATE404568T1 (enExample)
AU (1) AU2002302419B2 (enExample)
BR (1) BR0208244A (enExample)
CA (1) CA2440760C (enExample)
CY (1) CY1105507T1 (enExample)
CZ (1) CZ20032474A3 (enExample)
DE (2) DE50212652D1 (enExample)
DK (1) DK1368355T3 (enExample)
ES (2) ES2311920T3 (enExample)
HU (1) HUP0401211A3 (enExample)
IL (2) IL157895A0 (enExample)
MX (1) MXPA03008291A (enExample)
NO (1) NO20034031L (enExample)
NZ (2) NZ528639A (enExample)
PL (1) PL364388A1 (enExample)
PT (1) PT1368355E (enExample)
RU (1) RU2003129060A (enExample)
SK (1) SK11542003A3 (enExample)
WO (1) WO2002072585A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510064A (ja) * 2008-01-24 2011-03-31 アンドレイ・アレクサンドロビッチ・イワシェンコ 置換されたシクロアルキル［ｅ又はｄ］ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体のアンタゴニスト、その調製の方法及び使用
JP2011510063A (ja) * 2008-01-24 2011-03-31 アンドレイ・アレクサンドロビッチ・イワシェンコ ２−アルキルアミノ−３−（アリールスルホニル）−シクロアルキル［ｅ又はｄ］ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製の方法及び使用
JP2012513400A (ja) * 2008-12-22 2012-06-14 シェーリング コーポレイション γ−セクレターゼ調節剤
JP2016512844A (ja) * 2013-03-15 2016-05-09 クロモセル コーポレイション 疼痛の処置のためのナトリウムチャネルモジュレーター
JP2016532716A (ja) * 2013-09-10 2016-10-20 クロモセル コーポレイション とう痛及び糖尿病の治療用ナトリウムチャネル調節物質

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL382706A1 (pl) * 2002-08-26 2007-11-26 Takeda Pharmaceutical Company Limited Związek modulujący receptor wapnia i jego zastosowanie
UA81453C2 (en) * 2003-02-27 2008-01-10 Pyrazolopyridine derivates
GB0404434D0 (en) 2004-02-27 2004-03-31 Novartis Ag Organic compounds
WO2005112936A1 (en) * 2004-05-14 2005-12-01 The Regents Of The University Of Michigan Compositions and methods relating to protein kinase inhibitors
AR050188A1 (es) * 2004-08-03 2006-10-04 Uriach Y Compania S A J Compuestos heterociclicos condensados utiles en terapia como inhibidores de quinasas p38 y composiciones farmaceuticas que los contienen
EP1736475A1 (en) * 2005-06-21 2006-12-27 Ferrer Internacional, S.A. Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates
KR100838692B1 (ko) 2007-07-11 2008-06-16 한국화학연구원 7-(3′,4′-디알콕시페닐)-4,5,6,7-테트라히드로피라졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는천식 및 만성폐쇄성 폐질환을 포함한 염증관련 질환,관절염, 아토피 피부염, 암 및 뇌질환의 치료 및 예방을위한 약제학적 조성물
RU2376291C1 (ru) * 2008-05-07 2009-12-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 3,5-ДИАМИНО-4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 2-АМИНО-3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2374249C1 (ru) * 2008-09-17 2009-11-27 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ ЦИКЛОАЛКАНО[е ИЛИ d]ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2369600C1 (ru) * 2008-01-24 2009-10-10 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
JP2012504663A (ja) * 2008-10-06 2012-02-23 アンドレイ・アレクサンドロビッチ・イワシェンコ 置換された３−アリールスルホニル−ピラゾロ［１，５−ａ］ピリミジン、セロトニン５−ＨＴ６受容体アンタゴニスト、その調製のための方法及び使用
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
CN102775412B (zh) * 2012-08-21 2013-05-01 四川大学 一种镇静催眠的化合物及其制备方法和用途
CN102977106B (zh) * 2012-12-12 2014-12-10 中国药科大学 一类具有外周镇痛作用的κ阿片受体激动剂
WO2016123629A1 (en) * 2015-01-30 2016-08-04 Vanderbilt University Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CA3002144C (en) 2015-10-16 2024-01-23 Eisai R&D Management Co., Ltd. Ep4 antagonists
WO2018133835A1 (en) * 2017-01-20 2018-07-26 National Institute Of Biological Sciences, Beijing Nucleoside analogue regulating mammalian circadian rhythm
AU2018257332B2 (en) 2017-04-27 2021-11-04 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2018199235A1 (ja) * 2017-04-27 2018-11-01 武田薬品工業株式会社 複素環化合物
CN113354644B (zh) * 2020-03-04 2023-07-04 烟台药物研究所 一类用作dpp-iv抑制剂的吡唑并嘧啶结构的化合物及应用
IL297963A (en) 2020-05-07 2023-01-01 Adorx Therapeutics Ltd Antagonists of the adenosine a2a receptor
CN116023382B (zh) * 2023-02-22 2025-09-23 北京师范大学 一种合成手性四氢吡唑并[1,5-a]嘧啶的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63183584A (ja) * 1986-10-16 1988-07-28 アメリカン・サイアナミド・カンパニー ４，５−ジヒドロおよび４，５，６，７−テトラヒドロピラゾロ〔１，５−ａ〕ピリミジン類

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264773A1 (en) 1986-10-16 1988-04-27 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines
NZ233641A (en) * 1989-05-16 1992-07-28 Merrell Dow Pharma Quinoline and thienopyridine derivatives and excitatory amino acid antagonistic pharmaceutical compositions
GB9206266D0 (en) * 1992-03-23 1992-05-06 Merck Sharp & Dohme Therapeutic agents
FR2717812B1 (fr) * 1994-03-28 1996-05-10 Rhone Poulenc Rorer Sa Indeno[1,2-e]pyrazine-4-ones, leur préparation et les médicaments les contenant.
FR2722786B1 (fr) * 1994-07-20 1996-08-23 Rhone Poulenc Rorer Sa Derives de 4-hydroxy-3-phenyl-indeno(1,2-b)pyridine-2(1h)- one, leur preparation et les medicaments les contenant
DE4444815A1 (de) * 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
JP2003288537A (ja) 2000-09-25 2003-10-10 Everyd.Com:Kk 商品宅配システムおよび方法
DE10112197A1 (de) 2001-03-14 2002-09-19 Gruenenthal Gmbh Substituierte Pyrazolo- und Thiazolopyrimidine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63183584A (ja) * 1986-10-16 1988-07-28 アメリカン・サイアナミド・カンパニー ４，５−ジヒドロおよび４，５，６，７−テトラヒドロピラゾロ〔１，５−ａ〕ピリミジン類

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510064A (ja) * 2008-01-24 2011-03-31 アンドレイ・アレクサンドロビッチ・イワシェンコ 置換されたシクロアルキル［ｅ又はｄ］ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体のアンタゴニスト、その調製の方法及び使用
JP2011510063A (ja) * 2008-01-24 2011-03-31 アンドレイ・アレクサンドロビッチ・イワシェンコ ２−アルキルアミノ−３−（アリールスルホニル）−シクロアルキル［ｅ又はｄ］ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製の方法及び使用
JP2012513400A (ja) * 2008-12-22 2012-06-14 シェーリング コーポレイション γ−セクレターゼ調節剤
JP2016512844A (ja) * 2013-03-15 2016-05-09 クロモセル コーポレイション 疼痛の処置のためのナトリウムチャネルモジュレーター
JP2016532716A (ja) * 2013-09-10 2016-10-20 クロモセル コーポレイション とう痛及び糖尿病の治療用ナトリウムチャネル調節物質

Also Published As

Publication number Publication date
CY1105507T1 (el) 2010-04-28
CA2440760C (en) 2010-02-09
NZ528639A (en) 2005-07-29
EP1368355A2 (de) 2003-12-10
EP1637533A1 (de) 2006-03-22
DK1368355T3 (da) 2006-10-09
RU2003129060A (ru) 2005-04-10
ES2311920T3 (es) 2009-02-16
DE50212652D1 (de) 2008-09-25
CN1318422C (zh) 2007-05-30
US7135568B2 (en) 2006-11-14
PT1368355E (pt) 2006-09-29
NO20034031L (no) 2003-10-21
EP1368355B1 (de) 2006-06-07
ATE328886T1 (de) 2006-06-15
AU2002302419B2 (en) 2007-01-18
ES2263779T3 (es) 2006-12-16
KR20030082982A (ko) 2003-10-23
CA2440760A1 (en) 2002-09-19
HUP0401211A3 (en) 2008-03-28
NO20034031D0 (no) 2003-09-11
CN1507447A (zh) 2004-06-23
EP1637533B1 (de) 2008-08-13
IL157895A (en) 2009-12-24
US20040127508A1 (en) 2004-07-01
ATE404568T1 (de) 2008-08-15
WO2002072585A2 (de) 2002-09-19
DE50207103D1 (en) 2006-07-20
CZ20032474A3 (cs) 2003-12-17
IL157895A0 (en) 2004-03-28
MXPA03008291A (es) 2003-12-11
HK1061034A1 (en) 2004-09-03
BR0208244A (pt) 2004-03-02
NZ540574A (en) 2006-11-30
SK11542003A3 (sk) 2004-07-07
PL364388A1 (en) 2004-12-13
WO2002072585A3 (de) 2003-02-20
HUP0401211A2 (hu) 2004-10-28

Similar Documents

Publication Publication Date Title
US7135568B2 (en) Substituted pyrazolopyrimidines and thiazolopyrimidines
CN104884458B (zh) 作为蛋白质激酶抑制剂的稠合杂环化合物
SK4622002A3 (en) Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives, method for producing thereof and medicaments comprising said compounds
JP6284546B2 (ja) Ｃｆｔｒチャネルを阻害するための三環式化合物
EP1326613A1 (de) Verwendung von substituierten imidazo 1,2-a]pyridin-, -pyrimidin- und -pyrazin-3-yl-amin-derivaten zur herstellung von medikamenten zur nos-inhibierung
TW201720829A (zh) 哌喃并二吡啶化合物
AU2020302092A1 (en) Rho kinase inhibitors and compositions and methods of use thereof
JP4315678B2 (ja) 置換された３，４−ジヒドロ−ピリド［１，２−ａ］ピリミジン類
JP2002504883A (ja) コリン受容体リガンドとしての７−アザビシクロ［２．２．１］−ヘプタン及び−ヘプテン誘導体
DE10153344A1 (de) Verwendung von substituierten Pyrazolopyrimidinen als Liganden von Nucleosid-Transport-Proteinen und/oder von Purinorezeptoren
HK1061034B (en) Substituted pyrazolopyrimidines and thiazolopyrimidines
DE10112197A1 (de) Substituierte Pyrazolo- und Thiazolopyrimidine
TWI602818B (zh) 稠合雜環化合物作爲蛋白激酶抑制劑
WO2026080768A1 (en) Kcc2 potentiators and uses thereof
US20030220322A1 (en) Substituted 3,4-dihydro-pyrimido[1,2a]pyrimidines and 3,4-dihydro-pyrazino[1,2a]pyrimidines, and methods for their preparation and use

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090501

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090602

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090609

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100305

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100331

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100518

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100727